{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:59:51Z","timestamp":1777658391295,"version":"3.51.4"},"reference-count":14,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Novel immune\u2010modulating anticancer drugs are being used with increasing frequency. With increased use, there are more frequent cases of toxicities caused by these drugs, termed immune\u2010related adverse events (irAEs). We present a case in which we successfully treated a case of severe, steroid\u2010refractory, nivolumab\u2010induced myocarditis with therapeutic plasma exchange (TPE). Nivolumab is an immune checkpoint inhibitor (ICI) which blocks programmed death receptor\u20101 (PD\u20101). This blockade allows for enhanced T\u2010cell function and increased anti\u2010tumor response. The patient presented with signs and symptoms of heart failure and was found to have a significantly depressed cardiac ejection fraction. Over the course of her five TPE procedures, she improved clinically and was discharged home with improved left ventricular ejection function. This case suggests an emerging role of TPE in the management of severe ICI\u2010induced toxicity, such as myocarditis.<\/jats:p>","DOI":"10.1002\/jca.21890","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T23:00:44Z","timestamp":1614639644000},"page":"645-648","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Immune checkpoint inhibitor toxicity: A new indication for therapeutic plasma exchange?"],"prefix":"10.1002","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7924-2509","authenticated-orcid":false,"given":"Frances","family":"Compton","sequence":"first","affiliation":[{"name":"Carter BloodCare  Bedford Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pathology UT Southwestern Medical Center  Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Sarode","sequence":"additional","affiliation":[{"name":"Department of Pathology UT Southwestern Medical Center  Dallas Texas USA"},{"name":"Department of Internal Medicine (Hematology\/Oncology) UT Southwestern Medical Center  Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelework","family":"Wodajo","sequence":"additional","affiliation":[{"name":"Department of Pathology UT Southwestern Medical Center  Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3170-6482","authenticated-orcid":false,"given":"Amena","family":"Usmani","sequence":"additional","affiliation":[{"name":"Department of Pathology UT Southwestern Medical Center  Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Burner","sequence":"additional","affiliation":[{"name":"Department of Pathology UT Southwestern Medical Center  Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Berlacher","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (Cardiology) UT Southwestern Medical Center  Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7244-7181","authenticated-orcid":false,"given":"Nicole","family":"De Simone","sequence":"additional","affiliation":[{"name":"Department of Pathology UT Southwestern Medical Center  Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,3]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00748-2"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.05.010"},{"key":"e_1_2_6_4_1","unstructured":"Opdivo (Nivolumab) drug label.Updated March2019.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125554s058lbl.pdf"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2018.03.012"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21705"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1901677"},{"key":"e_1_2_6_9_1","unstructured":"Orencia (abatacept) drug label.Updated March2017.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125118s209lbl.pdf"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0130"},{"key":"e_1_2_6_12_1","unstructured":"RheumInfo website.https:\/\/rheuminfo.com\/medications\/cellcept\/. Accessed January 23 20192019."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2019.100420"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2019.07.008"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm955"}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.21890","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jca.21890","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.21890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T18:38:18Z","timestamp":1693334298000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.21890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1002\/jca.21890"],"URL":"https:\/\/doi.org\/10.1002\/jca.21890","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"value":"0733-2459","type":"print"},{"value":"1098-1101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"2020-07-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}